Literature DB >> 45558

Methotrexate nephrotoxicity.

R M Fox1.   

Abstract

The use of high dose methotrexate therapy in the treatment of malignant disease has been complicated by nephrotoxicity. Analysis of the basic physico-chemical properties of methotrexate has allowed the development of improved techniques of administering methotrexate, at high dose, which greatly reduces the incidence of nephrotoxicity.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 45558

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol Suppl        ISSN： 0143-9294


  6 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

Authors:  S Laohavinij; S R Wedge; M J Lind; N Bailey; A Humphreys; M Proctor; F Chapman; D Simmons; A Oakley; L Robson; L Gumbrell; G A Taylor; H D Thomas; A V Boddy; D R Newell; A H Calvert
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Theoretically required urinary flow during high-dose methotrexate infusion.

Authors:  K Sasaki; J Tanaka; T Fujimoto
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Practical issues with high dose methotrexate therapy.

Authors:  Osama M Al-Quteimat; Mariam A Al-Badaineh
Journal:  Saudi Pharm J       Date:  2014-04-13       Impact factor: 4.330

Review 5.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

6.  Acute Kidney Injury Following High-Dose Methotrexate Administration in a Day Care Hospital.

Authors:  Srimanta Chandra Misra; Alberto Santagostino; Gerard Dine; Larence Bonhomme Faivre
Journal:  Drug Saf Case Rep       Date:  2019-11-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.